Genetics of chromaffin tumors

References

• Tischler AS, Kimura N, McNicol AM. Pathology of pheochromocytoma and extra-adrenal paraganglioma. Ann. NY Acad. Sci.1073, 557–570 (2006).
   PubMed Web of Science ®Google Scholar
• Pacak K, Eisenhofer G, Ahlman H et al. Pheochromocytoma: recommendations for clinical practice from the first international symposium. Nat. Clin. Pract. Endocrinol. Metab.3, 92–102 (2007).
   PubMedGoogle Scholar
• Amar L, Baudin E, Burnichon N et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J. Clin. Endocrinol. Metab.92, 3822–3828 (2007).
   Google Scholar
• Neumann HP, Vortmeyer A, Schmidt D et al. Evidence of MEN-2 in the original description of classic pheochromocytoma. N. Engl. J. Med.357, 1311–1315 (2007).
   Google Scholar
• Neumann HP, Bausch B, McWhinney SR et al. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med.346, 1459–1466 (2002).
   PubMed Web of Science ®Google Scholar
• Amar L, Bertherat J, Baudin E et al. Genetic testing in pheochromocytoma and functional paraganglioma. J. Clin. Oncol.23, 8812–8818 (2005).
   PubMed Web of Science ®Google Scholar
• Gimenez-Roqueplo AP, Lehnert H, Mannelli H et al. Phaeochromocytoma, new genes and screening strategies. Clin. Endocrinol. (Oxf.)65, 699–705 (2006).
   PubMedGoogle Scholar
• Plouin PF, Gimenez-Roqueplo AP. The genetic basis of pheochromocytoma: who to screen and how? Nat. Clin. Pract. Endocrinol. Metab.2, 60–61 (2006).
   Google Scholar
• Maher ER and Eng C. The pressure rises: update on the genetics of phaeochromocytoma. Hum. Mol. Genet.11, 2347–2354 (2002).
   PubMed Web of Science ®Google Scholar
• Gutmann DH, Aylsworth A, Carey JC et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA278, 51–57 (1997).
   PubMed Web of Science ®Google Scholar
• Lee MJ, Stephenson DA. Recent developments in neurofibromatosis type 1. Curr. Opin. Neurol.20, 135–141 (2007).
   PubMed Web of Science ®Google Scholar
• Bausch B, Borozdin W, Neumann HP et al. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N. Engl. J. Med.354, 2729–2731 (2006).
   PubMed Web of Science ®Google Scholar
• Bausch B, Borozdin W, Mautner VF et al. Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J. Clin. Endocrinol. Metab.92, 2784–2792 (2007).
   PubMed Web of Science ®Google Scholar
• Radtke HB, Sebold CD, Allison C, Haidle JL, Schneider G. Neurofibromatosis type 1 in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J. Genet. Couns.16, 387–407 (2007).
   PubMedGoogle Scholar
• Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJ, Hofstra RM. Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet.22, 627–636 (2006).
   PubMed Web of Science ®Google Scholar
• Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab.86, 5658–5671 (2001).
   PubMed Web of Science ®Google Scholar
• Machens A, Niccoli-Sire P, Hoegel J et al. Early malignant progression of hereditary medullary thyroid cancer. N. Engl. J. Med.349, 1517–1525 (2003).
   PubMed Web of Science ®Google Scholar
• Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N. Engl. J. Med.353, 1105–1113 (2005).
   PubMedGoogle Scholar
• Lonser RR, Glenn GM, Walther M et al. von Hippel–Lindau disease. Lancet361, 2059–2067 (2003).
   PubMed Web of Science ®Google Scholar
• Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER. Genotype-phenotype correlations in von Hippel–Lindau disease. Hum. Mutat.28, 143–149 (2007).
   PubMed Web of Science ®Google Scholar
• Baysal BE. On the association of succinate dehydrogenase mutations with hereditary paraganglioma. Trends Endocrinol. Metab.14, 453–459 (2003).
   PubMed Web of Science ®Google Scholar
• Bayley JP, Devilee P, Taschner PE. The β mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency. BMC Med. Genet.6, 39 (2005).
   PubMed Web of Science ®Google Scholar
• Mannelli M, Ercolino T, Giachè V, Simi L, Cirami C, Parenti G. Genetic screening for pheochromocytoma: should SDHC gene analysis be included. J. Med. Genet.44, 586–587 (2007).
   Google Scholar
• Baysal BE. Clinical and molecular progress in hereditary paraganglioma. J. Med. Genet.45, 689–694 (2008).
   PubMed Web of Science ®Google Scholar
• Hensen EF, Jordanova ES, van Minderhout IJ et al. Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene23, 4076–4083 (2004).
   PubMed Web of Science ®Google Scholar
• Gimenez-Roqueplo AP, Favier J, Rustin P et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res.63, 5615–5621 (2003).
   PubMed Web of Science ®Google Scholar
• Timmers HJ, Pacak K, Bertherat J et al. Mutations associated with succinate dehydrogenase D-related malignant paragangliomas. Clin. Endocrinol. (Oxf.)68, 561–566 (2008).
   Google Scholar
• Pasini B, McWhinney SR, Bei T et al. Clinical and molecular genetics of patients with the Carney–Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur. J. Hum. Genet.16, 79–88 (2008)
   PubMed Web of Science ®Google Scholar
• Eng C. SDHB – a gene for all tumors? J. Natl Cancer Inst.100(17), 1193–1195 (2008).
   Google Scholar
• Brière JJ, Favier J, El Ghouzzi V et al. Succinate dehydrogenase deficiency in human. Cell Mol. Life Sci.62, 2317–2324 (2005).
   PubMed Web of Science ®Google Scholar
• Benn DE, Gimenez-Roqueplo AP, Reilly Jr et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J. Clin. Endocrinol. Metab.91, 827–836 (2006).
   PubMed Web of Science ®Google Scholar
• Dahia PL, Ross KN, Wright ME et al. A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet.1, 72–80 (2005).
   PubMedGoogle Scholar
• Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat. Rev. Cancer8(12), 967–975 (2008).
   PubMed Web of Science ®Google Scholar
• Gimenez-Roqueplo AP, Favier J, Rustin P et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet.69, 1186–1197 (2001)
   PubMed Web of Science ®Google Scholar
• Brière JJ, Favier J, Bénit P et al. Mitochondrial succinate is instrumental for HIF1α nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum. Mol. Genet.14, 3263–3269 (2005).
   PubMed Web of Science ®Google Scholar
• Selak MA, Armour SM, MacKenzie ED et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell7, 77–85 (2005).
   PubMed Web of Science ®Google Scholar
• Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. Loss of the SDHB, but not the SDHA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol. Cell Biol.28, 718–731 (2008).
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer.8, 865–873 (2008).
   PubMed Web of Science ®Google Scholar
• Maxwell PH. A common pathway for genetic events leading to pheochromocytoma. Cancer Cell8, 91–93 (2005).
   PubMedGoogle Scholar
• Joshua AM, Ezzat S, Asa SL et al. Rationale and evidence for sunitnib in the treatment of malignant paraganglioma/pheochromocytoma (MPP). J. Clin. Endocrinol. Metab.94(1), 5–9 (2008).
   Google Scholar
• Jimenez C, Cabanillas ME, Santarpia L et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel–Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel–Lindau disease-related tumors. J. Clin. Endocrinol. Metab.94(2), 386–391 (2008).
   Google Scholar
• Schlisio S, Kenchappa RS, Vredeveld LC et al. The kinesin KIF1Bβ acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev.22(7), 884–893 (2008)
   PubMed Web of Science ®Google Scholar
• Ladroue C, Carcenac R, Leporrier M et al.PHD2 mutation and congenital erythrocytosis with paraganglioma. N. Engl. J. Med.359(25), 2685–2692 (2008).
   PubMed Web of Science ®Google Scholar
• van Baars F, van den Broek P, Cremers C, Veldman J. Familial non-chromaffinic paragangliomas (glomus tumors): clinical aspects. Laryngoscope91, 988–996 (1981).
   Google Scholar
• Mariman EC, van Beersum SE, Cremers CW et al. Analysis of a second family with hereditary non-chromaffin paragangliomas locates the underlying gene at the proximal region of chromosome 11q. Hum. Genet.91, 357–361 (1993).
   Google Scholar
• Dahia PL, Hao K, Rogus J et al. Familial Pheochromocytoma Consortium. Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res.65, 9651–9658 (2005).
   PubMed Web of Science ®Google Scholar
• Neumann HP, Pawlu C, Peczkowska M et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA292, 943–951 (2004).
   PubMed Web of Science ®Google Scholar
• Schiavi F, Boedeker CC, Bausch B et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA294, 2057–2063 (2005).
   PubMed Web of Science ®Google Scholar
• Bornstein SR, Gimenez-Roqueplo AP. Genetic testing in pheochromocytoma: increasing importance for clinical decision making. Ann. NY Acad. Sci.1073, 94–103 (2006).
   PubMed Web of Science ®Google Scholar
• Jiménez C, Cote G, Arnold A et al. Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes. J. Clin. Endocrinol. Metab.91, 2851–2852 (2006).
   PubMed Web of Science ®Google Scholar
• Pigny P, Bauters C, Do Cao C et al. Should genetic testing be performed in each patient with sporadic pheochromocytoma at presentation? Eur. J. Endocrinol.160(2), 227–231 (2008).
   Google Scholar
• Erlic Z, Neumann HP. Clinical question: When should genetic testing be obtained in a patient with pheochromocytoma or paraganglioma? Clin. Endocrinol. (Oxf.) DOI: 10.1111/j.1365-2265.2008.03480.x (2008) (Epub ahead of print).
   Google Scholar
• Gimenez-Roqueplo AP, Lahlou-Laforêt K. Psychological aspects of genetic diagnosis of endocrine tumors. Ann. Endocrinol. (Paris)66, 284–288 (2005).
   Google Scholar
• Fraser L, Watts S, Cargill A et al. Study comparing two types of screening provision for people with von Hippel–Lindau disease. Fam. Cancer6, 103–111 (2007).
   PubMedGoogle Scholar